The Technology UnStack: Culture Bio’s $15M Series A confirms a shift in biotechnology R&D : Biofuels Digest
Summary
In California, Culture Biosciences, the South San Francisco biotech company making biomanufacturing a digital experience, announced today a Series A financing of $15M, led by Cultivian Sandbox Ventures with participation from The Production Board and existing investors Verily Life Sciences, Section 32, YCombinator, and E14 Fund. Pivot Bio, Zymergen, Nektar, Clara Foods, Modern Meadow, C16, Geltor, Boost Biomes, Synlogic, and Asimov. “To date, we have provided biotech customers an on-demand way of running bioreactors, and given them the ability to monitor their experiments and visualize their data in the cloud,” explains Will Patrick. “The next generation of breakthrough products across industries will be biomanufactured: our customers use biology to produce everything from novel therapeutics to food proteins to renewable chemicals and materials. “By leveraging the massive amounts of structured data that they generate for customers, they are positioned to bring AI and machine learning into biomanufacturing in an impactful way.”